核心外片,设计用于修改和连续释放易布洛芬和拉贝普拉
Babar Khan1, Ho-Ik Choi2, Jeong-Su Ryu2
1Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad 44000, Pakistan.
International journal of pharmaceutics
|October 17, 2024
概括
新的核心外片可以立即释放拉贝普拉 (RAB) 和经过修改释放的布洛芬 (IBU). 这种双重作用的配方提供了与单一药物相比较的药理动力学,可能会减少ibuprofen.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 药理动力学 药理动力学
背景情况:
- 像布洛芬 (IBU) 这样的非类固醇抗炎药物可以引起胃肠道 (GI) 的副作用.
- 拉贝普拉 (RAB) 是一种质子抑制剂,通常与NSAID联合使用.
- 开发用于顺序释放药物的组合剂型是制药研究的一个关键挑战.
研究的目的:
- 开发和描述用于连续释放拉贝普拉 (RAB) 和布洛芬 (IBU) 的核心外片.
- 为了达到与单个药物配方可比的药理学特征.
- 为了减少与布洛芬相关的潜在胃肠道副作用.
主要方法:
- 核心片是使用湿颗粒法制造的.
- 配方通过对试验批量进行比较评估来优化配方.
- 评估了 beagle 狗的物理化学特性,储存稳定性和体内药理动力学.
主要成果:
- 核心外片显示RAB的立即释放 (99.5%在1小时内在pH1.2下) 和IBU的延迟释放 (88%在缓冲阶段).
- 在野狗的体内研究显示,RAB和IBU与单药片相比,RAB和IBU的血度 (Cmax) 相当或有所改善.
- 开发的药片表现出良好的长期和加速储存稳定性.
结论:
- 核心外平板电脑设计是一种可行的策略,可以同时使用RAB和IBU,并进行顺序释放.
- 这种方法有可能减轻与布洛芬治疗相关的胃肠道并发症.
- 该配方对管理炎症状况充满希望,同时提高患者的服从性.
相关概念视频
Drug Delivery: Enteral Route
385
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
385
Routes of Drug Administration: Enteral
3.3K
Medications can be administered through the enteral route using liquids, capsules, or tablets.
Enteral administration involves drug administration via the mouth in two ways: orally or sublingually.
Unlike sublingually drugs, drugs that are taken orally pass through the gastrointestinal (GI) tract and get metabolized by the liver. Once metabolized, the drug is absorbed into the systemic circulation, reaching different body parts via the bloodstream. However, while passing through the stomach,...
Enteral administration involves drug administration via the mouth in two ways: orally or sublingually.
Unlike sublingually drugs, drugs that are taken orally pass through the gastrointestinal (GI) tract and get metabolized by the liver. Once metabolized, the drug is absorbed into the systemic circulation, reaching different body parts via the bloodstream. However, while passing through the stomach,...
3.3K
Factors Influencing Drug Absorption: Pharmaceutical Parameters
121
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
121
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
179
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
179
Drugs for Treatment of Constipation-Predominant IBS
140
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
140
Drugs for Treatment of Diarrhea-Predominant IBS
151
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
151


